GlassScriptPhysician profile
Mark H Schwab
NPI 1134137722
$3,318.76
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.00 · 2021: $264 · 2022: $1,445 · 2023: $1,080 · 2024: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,219.91 | 2021-2024 | Ubrelvy, Vraylar, Linzess |
| Novo Nordisk INC | $444.74 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $441.94 | 2022-2024 | |
| Corcept Therapeutics | $247.75 | 2021-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $165.53 | 2021-2023 | Evusheld |
| Amgen INC. | $152.52 | 2022-2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $124.34 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.61 | 2021-2023 | Xifaxan |
| Daiichi Sankyo INC. | $81.56 | 2023-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $72.33 | 2024 | |
| Abbott Laboratories | $40.28 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.84 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $32.93 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.56 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2024 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $16.64 | 2023 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $15.68 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.92 | 2021 | |
| Allergan, INC. | $14.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.76 | 2021 | |
| Esperion Therapeutics, INC. | $13.27 | 2023 | Nexletol |
| Amarin Pharma, INC. | $12.45 | 2021 | |
| Eisai INC. | $12.10 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schwab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.